Related Experiment Video For chronic hepatitis B
Updated: Jun 30, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Metabolic dysfunction-associated fatty liver disease in chronic hepatitis B: dual effects on hepatocarcinogenesis and
Huihui Tao1, Yuxin Duan1, Guoyang Yu1
1Department of Laboratory Medicine, Naval Medical Centre, Naval Medical University, Shanghai, China.
Aim:
Chronic hepatitis B (CHB) remains a major global cause of hepatocellular carcinoma (HCC), particularly in regions with high hepatitis B virus endemicity. Meanwhile, metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a rapidly growing metabolic contributor to hepatocarcinogenesis. Their co-occurrence influences liver cancer development through complex biological interactions. This review aims to summarize recent advances regarding how CHB-MAFLD comorbidity affects HCC risk and the development of related predictive models.
Methods:
This review synthesizes evidence from recent clinical and basic research exploring the relationship between CHB-MAFLD comorbidity and cancer risk. It evaluates the performance of traditional and next-generation risk prediction models and examines the potential of artificial intelligence in integrating multimodal data to improve accuracy.
Results:
The underlying pathophysiology exhibits a dual nature. While metabolic disturbances can suppress hepatitis B virus replication and facilitate surface antigen clearance, metabolic dysfunctions such as obesity and diabetes independently accelerate fibrosis and increase cancer risk. This paradox originates from heterogeneous effects: simple steatosis may reduce risk, whereas cumulative metabolic abnormalities increase risk in a dose-dependent manner. Although traditional models retain prognostic value, their sensitivity is suboptimal. Next-generation models incorporating metabolic parameters have demonstrated improved accuracy. Furthermore, machine learning shows considerable potential for modeling complex non-linear interactions and enabling individualized risk prediction.
Conclusion:
This review summarizes how metabolic dysfunction-associated fatty liver disease influences cancer risk in patients with chronic hepatitis B. It provides a framework for identifying high-risk individuals to guide stratified, precision management strategies.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Chronic Pancreatitis II: Pathophysiology
Cirrhosis II: Pathophysiology
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

